{"id":91504,"date":"2026-11-18T17:20:00","date_gmt":"2026-11-18T17:20:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=91504"},"modified":"2026-11-19T02:16:49","modified_gmt":"2026-11-19T02:16:49","slug":"pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/","title":{"rendered":"Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing"},"content":{"rendered":"<p><em>North America Holds 42% of a USD 1.88 Trillion Market, Prescription Drugs 87% and Cancer 19%, While Biologics and Obesity Grow Fastest: Precedence Research Segment, Company and Buyer Intelligence<\/em><\/p>\n<p>Ottawa, Nov.  18, 2026  (GLOBE NEWSWIRE) &#8212; <img decoding=\"async\" height=\"62.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/5151a1ed-5981-43fa-b1fa-689238cacb82\/image1.png\" width=\"190.0px\" data-dpi=\"96\" data-filename=\"image1.png\" \/><\/p>\n<p><i>The global pharmaceutical market is valued at USD 1.88 trillion in 2026, up from USD 1.77 trillion in 2025, and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. The U.S. market is expected to grow from USD 552.72 billion in 2026 to about USD 963.52 billion by 2035.<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"338.47px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/eaa355c9-73ae-40e4-9da7-61fe62078fb4\/image2.png\" width=\"601.74px\" data-dpi=\"72\" data-filename=\"image2.png\" \/><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>Precedence Research today released updated <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=324R93NjBQVZIU7EWYNOoZ6nIqUlkHcnpxcsDWyZumI7D89epSClx7Hyxa4IyhET42yGqoWeTtzz5UgU4YfIWHMO0pRWMsUbXXxnwdunuT8KOb4wuWIsCxPVOAx11Yt9wQ_W66-ES-4Nt3hrGGYbI1hvi7U3BYoWOGxQuWeMN_kjXvRNhw_o2qHJ_FMfylkk\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>intelligence on the global pharmaceutical market<\/b><\/a>, covering prescription and over-the-counter medicines, small molecules, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7hEL0aJXf1IdrA6rO8dZM-wofmumky4_raBcSwzLtQw-47HiaJm5hWH0mmC5m4lAkCmb6lf4OH-6w0ewlZp60qY6feSulT7pFkUD_qKV00Dc8hwBawZIEiQFkK-JckZZ\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>biologics<\/b><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NkikqnkC8UPNGcWNi75SwpCajSa3eAlfjaE76vxTw6SDAF-2MzIRXdBZHQf9iDMIuy-nvQSyfs6Sjw5lmXncHZ0Ky5IQ2lZV14_Ww_hiERlm2-CUVeErr1iQ6bN0E4M9\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>biosimilars<\/b><\/a>, and the companies, channels and policies that shape them. The market is valued at USD 1.88 trillion in 2026 and is forecast to reach USD 3.20 trillion by 2035, adding about USD 1.32 trillion in annual sales.<\/p>\n<p>Growth is concentrated in a few therapy areas. Obesity is the fastest-growing disease area, oncology is the largest with 19% of revenue, and immunology continues to expand. Company results show the same pattern: Eli Lilly&#8217;s third-quarter 2026 revenue rose 39% to USD 24.4 billion on the strength of Mounjaro and Zepbound, AstraZeneca&#8217;s oncology sales grew 16% in the first nine months, and Roche&#8217;s pharmaceuticals division grew 7% at constant exchange rates.<\/p>\n<p>Policy is reshaping the industry at the same time. On April 2, 2026, the U.S. imposed Section 232 tariffs of up to 100% on imported patented drugs, with a 0% rate through January 2029 for companies that sign most-favored-nation (MFN) pricing agreements and commit to U.S. manufacturing. The administration links about USD 400 billion of U.S. manufacturing commitments to the policy. For drugmakers, generic producers, CDMOs, distributors, payers and investors, pricing, location of production and pipeline renewal are now the central strategic questions.<\/p>\n<p><b>Full report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fGxBY4lEcK48Yk_b_GiUOLCt4qN_gpmnuZkEvc552tgl4VpHVSW2zgBjN3cuz2lKBY3Mj_0BCmxxrgNgd1DSEbyi_Vj1foFcOzS6dgU2SEjhTZbEaPcfbsSAGxTLmB8-mdTcV0z89n0_ht-UA9gGoQUtrMiOXAo3fzijrfv35ML0SdSTZjAjmEkt_C1kH6YW\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmaceutical-market<\/a><\/p>\n<p><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fGxBY4lEcK48Yk_b_GiUOLCt4qN_gpmnuZkEvc552tiVWW_cjirqQafQweOpSNMg61nQTDZyX5F2Jwcf0mzKd1AxO8SwRN4DQv1bHWSWk9rZTGYN5a2tL08dQUdFwhfLdg49GZ2iEP4opXMMju-3KjI4GJCV-xgOaSXe8NpqxUA=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/sample\/6227<\/a><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/84a6abe0-66e6-4872-b7d5-36b039736fa0\/image3.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image3.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 1: Pharmaceutical Market Snapshot<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>The market grows steadily rather than explosively because strong growth in new medicines is partly offset by patent expiries, generic and biosimilar competition, and price controls. Net growth therefore depends on how quickly companies replace older revenue with new launches.<\/p>\n<p><b>Segment Intelligence: Dominant and Fastest-Growing Segments<\/b><\/p>\n<p>2026 values apply the published 2025 shares to the 2026 market size of USD 1.88 trillion and are modeled estimates.<\/p>\n<p><b>Pharmaceutical Market: Key Segments<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Segment<\/b><\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>2025 Share<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>2026 Value (modeled)<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Growth Signal<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Prescription drugs<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: top ; \">87<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: top ; \">%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 1,636 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest type; OTC grows fastest<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Branded products<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: top ; \">87<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: top ; \">%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 1,636 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest; generics grow fastest<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Conventional small molecules<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: top ; \">55<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: top ; \">%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 1,034 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest; biologics and biosimilars grow fastest<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Cancer (disease area)<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: top ; \">19<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: top ; \">%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 357 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest disease area; obesity grows fastest<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Oral (route)<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: top ; \">58<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: top ; \">%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 1,090 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest route; parenteral grows significantly<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Adults (age group)<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; padding-right: 0 ; text-align: right ;  vertical-align: middle; vertical-align: top ; \">64<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; text-align: left ;  vertical-align: middle; vertical-align: top ; \">%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">About USD 1,203 billion<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest; geriatric grows fastest<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Type and product.<\/b> Prescription and branded medicines dominate revenue. Over-the-counter drugs and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lf200muUhUlKDroIbBtO5NuwMHWsrP2F5x6RtfzscQg633OXYp9nH1krEybZUz0lGzlwvLYWsUiC4_R1-iV39zDjZ2qDhala2wv1u8xBuXHcrOxw_bi1Q55V1yfW__7LW0LEjl8Cy02CggC5ISVM9Pe_N8pD1nNnB9ZzLwIY1-skz4RqPIs0gQD6jPrDQNIAuAjnDmVg9te7SqALgZQ1W04pePHze6urxskDLTrwUcE=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>generic drugs grow fastest as patents expire and consumers self-treat more conditions<\/b><\/a>.<\/p>\n<p><b>Molecule and disease.<\/b> Small molecules still account for 55% of revenue, but biologics and biosimilars grow fastest. Cancer is the largest disease area, while obesity is the fastest-growing, driven by GLP-1 medicines.<\/p>\n<p><b>Channel.<\/b> Hospital pharmacies are the largest channel, and retail pharmacies grow fastest as more specialty and chronic-care drugs move into community settings.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Regional and Country Analysis<\/b><\/p>\n<p><b>Pharmaceutical Market by Region<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Region<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Position<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Key Facts<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Growth Signal<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">North America<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest, 42% (2025)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">U.S. USD 552.72B (2026) \u2192 about USD 963.52B (2035)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Tariffs and MFN pricing reshape supply<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Europe<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Major market and producer<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Home to Roche, Novartis, Sanofi, GSK, Novo Nordisk<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Exports to the U.S. affected by tariffs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Asia Pacific<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Fastest-growing<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">China and India manufacturing; Japan innovation<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Rising access and local innovation<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Latin America and MEA<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Emerging<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Brazil, Mexico, Gulf states<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Expanding coverage<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>North America.<\/b> The U.S. is the largest and most profitable market. The April 2026 Section 232 proclamation applies tariffs of up to 100% on imported patented drugs and ingredients, while companies that sign MFN pricing agreements and onshore production qualify for a 0% rate through January 20, 2029. Tariffs took effect on July 31, 2026, for 17 large manufacturers, and nine more companies, including Sun Pharma, Teva, CSL, Astellas and BeOne Medicines, signed MFN agreements on August 31, 2026, with USD 19.6 billion of U.S. manufacturing commitments.<\/p>\n<p><b>Europe.<\/b> Europe is both a major market and the largest exporter of medicines to the U.S. Roche reported nine-month 2026 pharmaceuticals sales of CHF 36.2 billion, up 7% at constant exchange rates, with Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo together growing 12%.<\/p>\n<p><b>Asia Pacific.<\/b> Asia Pacific is the fastest-growing region. China is a major source of new drug candidates licensed by Western companies, India is the largest supplier of generic medicines, and Japan&#8217;s Daiichi Sankyo and Takeda are major innovators.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>What Is Changing in the Industry<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/60e4a669-1257-4d21-94f2-f439f3590cc3\/image4.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image4.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 2: Policy and Company Milestones Reshaping Pharma, 2025\u20132026<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>U.S. pricing and tariffs are now linked.<\/b> Thirteen drugmakers signed MFN pricing deals in late 2025, and the April 2026 tariff proclamation made such deals, combined with U.S. manufacturing commitments, the route to a 0% tariff. Pfizer says its agreements lock in a 0% tariff into early 2029.<\/p>\n<p><b>What it indicates:<\/b> Lower U.S. net prices and higher U.S. manufacturing investment will reshape margins and supply chains through the end of the decade.<\/p>\n<p><b>Obesity and oncology are driving industry growth.<\/b> Lilly&#8217;s Mounjaro reached USD 10.7 billion and Zepbound USD 5.4 billion in the third quarter of 2026. AstraZeneca&#8217;s oncology revenue reached USD 21.9 billion in the first nine months, 47% of its total.<\/p>\n<p><b>What it indicates:<\/b> Companies with leading positions in GLP-1 medicines and cancer therapies are growing far faster than the market.<\/p>\n<p><b>Older franchises are under pressure.<\/b> Pfizer&#8217;s third-quarter revenue was flat at USD 16.6 billion as COVID-19 products declined, although non-COVID products grew 7% and launched and acquired products grew 32%. Roche continues to offset biosimilar erosion with newer medicines.<\/p>\n<p><b>What it indicates:<\/b> Replacing revenue lost to patent expiries and falling COVID demand is the central challenge for many large drugmakers.<\/p>\n<p><b>Deals are refilling pipelines.<\/b> GSK agreed to buy Nuvalent for USD 10.6 billion, Pfizer signed a collaboration with Innovent worth up to USD 10.5 billion, and Sun Pharma agreed to acquire Organon for USD 11.75 billion in 2026.<\/p>\n<p><b>What it indicates:<\/b> M&amp;A and licensing, especially of Chinese assets, will remain a major source of growth.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Key Market Drivers<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Rising chronic disease, obesity and cancer, and an aging population.<\/li>\n<li style=\"margin-bottom:4pt;\">Innovation in biologics, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QVGVJ_dVvz3N2eYQ0Xte7qlVmeBuUcsxSH0SR0GNKW4SEGn8InnTP_n3rnF_6v6Ex3UPWwvtMMf1iKJqz1NzDI1srjgJ1q2TynNd6SoKmRRu80qJXf8G5dU7xSAE3YhEIXnJB3TCixjn9rglLZb_xw6TKNPcE3ASTYm05avLWOk=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>cell and gene therapy<\/b><\/a> and targeted cancer drugs.<\/li>\n<li style=\"margin-bottom:4pt;\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qVmUbY95u3smnxCaPBjNpwy1zJ5moQR69z9U64X3xTB7mVN4fifvSR_---uEX5ZT_k-glCUDt9IfXTgEo1y1ORu_v8S3UGoS9c6h7K-lqs7sghi_Y01wXp_YnbgEPfsszgWxxv-Y1-jHfwZ_zeSJ4g==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Use of AI in drug discovery<\/b><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_4HGw-eRSeKiNMjUyOqMuumcbbSyN4dGFeEdCjdxVYOVfYxzBruUhtnYIVJaGnX6ySuudh3WS-7t6TpzFNzy7tU5xNTnp79CD6O0wZ7qu7dq16pCXw-y5huQPksBlAVt1O3cPe9sUko6b7O-Q0KxVw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>clinical trials<\/b><\/a>.<\/li>\n<li style=\"margin-bottom:4pt;\">Expanding access in Asia Pacific and emerging markets.<\/li>\n<li style=\"margin-bottom:4pt;\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s4-tnvs1Xky2epJfqjabcvAuT-xLUiiviafddEKGz4dGYvITiCVmm9e9DWVk68FatE6Td8djR-Daf0sOpHZUfq7yaodrkMHVTUx2WUWP8LOOXe38ofoAYvKrws8H__Kg3IHHJcgzakai9RVEA4xDZA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Growth of telehealth<\/b><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AQlCAXmIDGVprmlbtPZuQ36XmWOjwL36CJbp6AV4n86mON3Ez5x8xmp3AYtalcOly_d2P8xnBflywHD-649oMvtejAlwldTK90Y1lSPGp1RsAgB14Ok18W2I9PY-AlXhgEIoASQR3PHNtIx6zEdWJQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>digital health<\/b><\/a> channels.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Major Challenges<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Patent expiries and biosimilar competition.<\/li>\n<li style=\"margin-bottom:4pt;\">U.S. MFN pricing, Medicare negotiation and 340B changes.<\/li>\n<li style=\"margin-bottom:4pt;\">Tariffs and supply chain relocation costs.<\/li>\n<li style=\"margin-bottom:4pt;\">High R&amp;D costs and late-stage failures.<\/li>\n<li style=\"margin-bottom:4pt;\">Price controls and reimbursement pressure in Europe and China.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Emerging Opportunities<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Obesity<\/b>, the fastest-growing disease area.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Biologics and biosimilars<\/b>, the fastest-growing molecule types.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Generics and OTC<\/b>, the fastest-growing product and type segments.<\/li>\n<li style=\"margin-bottom:4pt;\">U.S. manufacturing and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FRF1ETsJahGESyMNYnFfoNHVBgH_4UYbwI_m7DQu3xFWQmJsE39SDv0HvgnPP8I95qb7A5DI0hx6fb3qTfKR7c1verTA657eIeh5mYW86O-_Bd7fNZqWT5ZrzDXajx4xgvKNTFpF4_hHGOquB-rUHrTcQYyky9FtjYrJMd3FoBfzX-mBLcRVvqWm4wrPwHeEdla3h6uRmpGyNBVVYaPaTvKWhJwjsdlyOlIhkomis4w=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>active pharmaceutical ingredient supply under new tariff rules<\/b><\/a>.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Geriatric medicine<\/b>, the fastest-growing age group.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Company and Competitive Intelligence<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/26347115-430c-4ec6-929a-6116a0adbe34\/image5.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image5.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 3: Leading Drugmakers, Third-Quarter 2026 Revenue<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>The industry is led by large innovative drugmakers, with Eli Lilly now the fastest-growing major company. Other leaders include Johnson &amp; Johnson, Roche, Merck &amp; Co., Pfizer, AstraZeneca, Novartis, AbbVie, Novo Nordisk and Sanofi. Generic and biosimilar producers such as Teva, Sandoz, Viatris and Sun Pharma serve the high-volume end of the market.<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Company<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Latest Reported Data<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Growth Drivers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Strategic Direction<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Eli Lilly<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 revenue USD 24.4B (+39%); 2026 guide USD 91\u201392B<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Mounjaro, Zepbound, Foundayo<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 50B U.S. manufacturing; obesity pipeline<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Merck &amp; Co.<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 revenue USD 18.1B; Keytruda USD 8.6B<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Keytruda, Keytruda Qlex, Gardasil<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Terns deal; replace Keytruda before 2028<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pfizer<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 revenue USD 16.6B; 2026 guide raised to USD 62\u201364B<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Launched and acquired products +32%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Innovent and Metsera deals; MFN agreement<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">AstraZeneca<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 revenue USD 16.2B (+7%); oncology 9M USD 21.9B (+16%)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Tagrisso, Imfinzi, Enhertu<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Oncology and ADCs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Roche<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">9M 2026 pharma sales CHF 36.2B (+7% CER)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Xolair, Hemlibra, Ocrevus, Vabysmo<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pipeline prioritization; Hansoh deal<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Novartis<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 sales USD 14.52B (+4%)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pluvicto, Kisqali<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Radioligand therapy investment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Amgen \/ Gilead<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 revenue USD 10.4B (+8%) \/ USD 8.3B (+7%)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Repatha, Imdelltra \/ HIV +18%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">MariTide; four Gilead acquisitions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Sun Pharma \/ Teva<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">MFN agreements (Aug 2026)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Generics and specialty<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">U.S. manufacturing commitments<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Customer and Buyer Intelligence<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Target Account Group<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Decision-Makers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Purchase Signals<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Commercial Opportunity<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Hospitals and health systems<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Chief Pharmacy Officer, P&amp;T Committee<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">New launches, budget reviews<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Formulary and supply contracts<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Payers and PBMs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pharmacy Director, Medical Director<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">MFN prices, biosimilar entry<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Value-based and rebate contracts<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pharma business development<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Head of BD, R&amp;D Head<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Patent expiries, pipeline gaps<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Licensing and M&amp;A<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CDMOs and API suppliers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">BD and Operations Heads<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Onshoring plans<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">U.S. manufacturing capacity<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Distributors and pharmacies<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Category and Procurement Heads<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Generic launches, specialty growth<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Distribution and specialty services<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>How Precedence Research Supports Decision-Making<\/b><\/p>\n<p><b>Master Dataset<\/b> provides segment, regional and company data for pharmaceuticals and adjacent markets such as the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X36rysMLaz9-N1mszbPiPog6Pe4-4yc7n33oIHkOX9J--A5cVKjPgRV2TegcOzTeyfTZCnaRjR9ebrnYq8HCWgZnv5yANZsytmhR_IVpzn_7EpzRakvlJlsV19FUlOVW9m_WJI_wczZNDwPtwC95Pg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>U.S. pharmaceutical<\/b><\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7hEL0aJXf1IdrA6rO8dZM0DwEs83IN4MgPxm82li86ETO9O1XaiLHUElTQ3vlog5KPApUmLqkZamqUKZCKfNUrk8YYYfm3hEExxe2jXZ9PpQG0UEg-j-Vw15dKrveFyX\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>biologics<\/b><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lf200muUhUlKDroIbBtO5KQqAw22hL4MOnLL5yQY8kRRqUEbKoegX4g_fGXnnRFCOwOeg1hKEmCNe0D3yyHvGYE7c0nB2gyL6zhKDnERSE6dXP2sGr5cPd1dmQ2h1kmvomb43vyuQ5dBhlGc5dVRoQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>generic drugs markets<\/b><\/a>. It helps teams size demand by type, molecule, disease, route and channel.<\/p>\n<p><b>Precedence Quadrant<\/b> compares drugmakers on growth, pipeline strength, patent exposure and manufacturing footprint, helping partners and investors benchmark leaders.<\/p>\n<p><b>Interactive Intelligence Dashboard<\/b> tracks results, approvals, deals, pricing agreements and tariff decisions, so commercial and strategy teams can respond quickly.<\/p>\n<p><b>Quality &amp; Manufacturing Intelligence<\/b> maps API, CDMO and finished-dose capacity by country, supporting onshoring and sourcing decisions.<\/p>\n<p><b>Customized Research<\/b> answers specific questions, such as the impact of MFN pricing on a portfolio, tariff exposure by product or opportunities in obesity and oncology.<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Solution<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>What It Provides<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>How It Helps<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Master Dataset<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Segment, region and company data on pharmaceuticals<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Sizes demand by disease and product<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Precedence Quadrant<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Drugmaker comparison on growth and pipeline<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Benchmarks leaders and partners<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Interactive Dashboard<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Live tracking of results, deals and policy<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Times pricing and investment moves<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Quality &amp; Manufacturing Intelligence<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">API, CDMO and plant capacity mapping<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Supports onshoring and sourcing<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Customized Research<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pricing, tariff and therapy-area studies<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Answers decision-specific questions<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Why Continuously Updated Intelligence Matters<\/b><\/p>\n<p>Pharmaceutical pricing, trade and pipeline news now changes month to month. Monthly updates suit teams tracking tariff and MFN decisions and new approvals. Quarterly updates match company earnings. Six-monthly updates help strategy teams follow policy and patent timelines, and annual updates support investors reviewing market size and share. Precedence Research offers all four update cycles.<\/p>\n<p><b>Strategic Outlook<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>CEOs and CXOs:<\/b> the market adds about USD 1.32 trillion by 2035; obesity, oncology and immunology will deliver most of it.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Strategy and business development teams:<\/b> licensing and M&amp;A remain the fastest way to replace revenue lost to patent expiries.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>R&amp;D leaders:<\/b> biologics, biosimilars and obesity medicines are the fastest-growing areas.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Procurement and supply teams:<\/b> plan for U.S. onshoring and API sourcing under the new tariff rules.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Investors:<\/b> companies with MFN agreements, strong pipelines and U.S. capacity are best positioned.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Manufacturers and CDMOs:<\/b> about USD 400 billion of U.S. manufacturing commitments create demand for capacity and services.<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Company Ecosystem<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/32a5bea3-41eb-484b-8959-12936f7f1b97\/image6.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image6.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 4: Pharma Leaders, Key 2026 Signals<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"446.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/b8973c9d-5e9a-4933-9360-352f457fc949\/image7.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image7.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 5: Pharmaceutical Company Ecosystem, 2026<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Call to Action<\/b><\/p>\n<p>To understand how pricing, tariffs and pipelines will shape the pharmaceutical market through 2035, explore the full report or speak with a Precedence Research analyst.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ3WKGxez0qDaT3KG_CFwPoIDKFz9gk6tKLDS06dWTP8ImxBzQhieEsNwhN1ZuGIaGfZKf2a3JMfMsaQdjz_myRBZ6TqcfFXcuuxjJF63zCjgmt8smVYvNNZRn8RQ3lmyV8Jl5oNXPVIUgwsVntCW6xG\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmaceutical-market<\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ2Qy-leNjJNqEIE9cxNd8-5R6MfZLf-eQPmRijEfVqB1ERcvRrxbLtKy2mFmW5zcZu59WYD8A4_PaEiJfDS3PMucvABmry5NcdhpkgvAryn24uxSFOczWBKEbavTaJyzFw=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/sample\/6227<\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Schedule a meeting:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ0INSsJ_dXTL2mUgU-ciYKKfjcJQrSiGTvL4qWohShPpkc8R0jtCvAyI2IvTEdmph4h1hLPv741OJVbriMhcVgmZkwySSrdk_-ZhoPeNyQn8BUpSsXdwjkLg-PIcOm9nXU=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/schedule-meeting<\/a>\n<\/li>\n<\/ul>\n<p><b>Fill out the form for relevant samples, case studies, and examples.<\/b> sales@precedenceresearch.com<\/p>\n<p><b>Related Reports<\/b><\/p>\n<ol style=\"list-style-type:decimal;\">\n<li style=\"margin-bottom:3pt;\">U.S. Pharmaceutical Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ3-07c2ZwhiY-9XPid4iXXQvULbNg45_aHSonDCHK5dfQqET09ztwAgdyjGqm_g_jG7_a6dBvKoOl5DXcE3BI257cFOUgpxS_85NV1lTQiY5DKgzV8KsthO5Aw9iiuks2dPdsjsaygxx6666yDiHsKw\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/us-pharmaceutical-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Biologics Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ0mJmINpJZhDHc7r-uj3sTTG3kvuLRjsjso1nNBDq2dPbt6UGP9IiUo0886JIFfEeW5qdIK47Djv7xo4ublHZOALJAwwr4usuMlxSuCHIg_jMYdSJSC9xOTECx3dado66I=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/biologics-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Biosimilars Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ0mJmINpJZhDHc7r-uj3sTTJXBJeE8Rgx4uO4sNZoy0BE8bTmKQuqsEHQ7KgUT4D2wG00F69rbQ4YbWhGP6vUg1iLmNjdH0aTF41A_4iMFab3JPnfIdvmGlcUkb16TOoNcp4VldW39FPFeXb0kEGGKW\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/biosimilars-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Generic Drugs Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ20o6g81mfmN06JLuc1iNCx-koDYSHI5Ogq_4Pe2kS5-pPxvqZpXUm_Sqnr0wm3bC0QZ6YGmp18coiP7S4KTtDxBtusBnypBtdX-hJbRkIJpsUTN4cO2qnflyomMlfcRfn7OvEi-0UZaxW1moK-_f0U\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/generic-drugs-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Over the Counter Drugs Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ3WARDrtslVad6qWOrYhkm5eQyZTFGzjWTKFhnRr20jLEuEMfOp3Uubkh9PYTTTT6CKkizyMaz28Q_9bnZiJXYfJuMddsvGNj5ehqMo29ynceHZ7Oku6fhVsk_STYuxlwPOZ1PXS7t3Joptu7FmAK94cxE2B-Epnta3NrJo-qg-Mw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/over-the-counter-drugs-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Active Pharmaceutical Ingredient Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ34Ajt6k7JzuWKyxWO7rzRBlBw57toimZGWSF61p3KKp_mfuhP0vRgAj2hHSAFGtE9Xxl7KaJ_Mb48vEtKH7uOYUpnAnxUIZ2exeTljSCV-9kDRkr9WT9OYy_VBxQQnEAWeht0A0_rb1O2ykW8qWnjpcxz-D_OSNdXbFnJFaa-CtMcdcFyQg8SZG9xMlRuSmWU=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/active-pharmaceutical-ingredient-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Pharma 4.0 Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ3WKGxez0qDaT3KG_CFwPoI-6i2ku9lLcDuL8VLrez9q6GdvySH_KKAzjQ0jDSyxIm-OZ9WN5VSEJn-9KWd1FTdM4sMG5zNUJf6UJ2g_2a8rxIdX7QhaNL6PttU5qXisFw=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharma-4-0-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Pharmaceutical Analytical Testing Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ3WKGxez0qDaT3KG_CFwPoIFnCdOUCsibxNylOJlN5Z8FB_AARq7BOYt8iICXrkd-O7dBYyoNfKOE2AvQyFimE1OIbUqTI94GYNy-T1slCZZ2V7jEpNhMGZVX0qw-cgtb46aNpGGqMZy9zN7Aai6zOaiHC-hbguAyuYjTG43BlT1II-8aMRf4lYHhyC606ZZNg=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmaceutical-analytical-testing-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Pharmaceutical Water Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ3WKGxez0qDaT3KG_CFwPoIcpnqEuUPG_ey21P6zeFg7fSkptM3yrMopXhImBCUpW469fQa26KEw1WDOB30xsrF4SPMwmrh27LFws2xgKvl3R2ptatjlNAEADGEPeNbECMCjYzAEFOCnoP6c4TxGa0ee_agz0xDnKdFvPAcrz9UQg==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmaceutical-water-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Artificial Intelligence in Drug Discovery Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ1fIRPZKVDT9l3uCpEap1_e1mh3_KJiHk5GN4kOrbeIUzRD_IhHOavVyJ4QoOQ0QSMZAKvu9XG9g9hIHEQqj9e2P-JIgVGAsYHiD0ROHNBPbilylfwC5oY8oyUjCmqp0xkuGzIVePcfchpmLXxNQD8-D8iUFbugYePOm5xxQ7ztl7J9TsK5p9K0CmYqSrGSoyaagAYwFGJNmVKk1MBKJbZJ\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/artificial-intelligence-in-drug-discovery-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">AI in Clinical Trials Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ1vbu-uFrNdVeI6VoOe4hDa-xPwYF32QG0EGdfkn8vHDVj36X2kJw8j-Yk53MubKgdyPlMPESViabmmo6s4nCT7xAJ_8Ra5kHRQnwO4rjVVfmogvjHtvSyaGIIpxOF8-DeEYaaJ0QZWEFK5at_t6HqtFCAIS4Uqgw6VCQNwh3obIg==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/ai-in-clinical-trials-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Oncology Clinical Trials Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ2VV_5-QxtwlafbDPG6e5RRVc1vXGYa6Vg_6KC_HySZGUCKBZkeBXaYmukwMniHtfrn2RKSh2FbQ8wcwt8hV81hG7u4jdBJnyyQLYwA3Gti_bQB43orMI9zjo0dwsTTCsPMWhG1KpaBiDvdfEWAMVkclcaHPJXuSpbUEIbfGEKAJw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/oncology-clinical-trials-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Clinical Trials Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ3WYCgERghIbtJS9iDbb4Jsbs3unbfd9PiocYqcCHDjNd1A9T0GXYae8-FDbIy8730YnFkQ0OWCwN10qepNQG5opL50pohqTYEtYkU4bcWNeP2sj9eICMBOAZ0i-K_zkYkyRJdzmMHYCXHle_HlFPJ9\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/clinical-trials-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Drug Discovery Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ2SniubdLvygfhNp052ywH4svlqcN_jraIsQfxlNQJYQuF96Q7CbihZj94Nkyt49FBb5WPiT8oiA4a5rQlsy-r-L3YjhYFyB8UacPWQIMtd6k7XtXL8gDg7hZc2s9f8s_prm09hsUe43m6jbe9E_TRy\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/drug-discovery-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Cell and Gene Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ1IaMxlZ2r64FSjqk-g4Nw4rV3yLVge6_AEZPBqDouvC5NJ95gwxdllhKh7wvN4NwYim7Ybw--_BTxsJlCNV6SsspVGyaFqYB-uDGM9_E157KKRuiKRiZG1BRGrXwxlfzRv71DpUhl2Kshs3hd1IYzmmxjkMTuwsrwQIJxEn_LU2A==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/cell-and-gene-therapy-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Vaccines Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ3_6nSIvAFw60Edxsc9Zu4xRWTqzFHKMyZknJiqimNdhMbJ7CGwEmeW-Un_5rW9n4fNOw0kBWkZiBra2P5Lq_Af81HU8a8GwDxjpbrU-gp2i_-8S0-s_LKmKqRsGGWEnR0=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/vaccines-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Personalized Medicine Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ2iIqDjrQVkPY92sRO2NSKDmKKsdcYTJmjpB6tKQ2UglFL5Ny3lhI9aJ3CC-YT2kb0XtSIuEdhudY96cHh_6yiNxwDLjzBXRjnR-aDP7EwGscAfG-UEEH4FDUhkoJnp76g1AMO6r-GdRGxNT6kePzZCJBNmzqh4U8E6QGLosJv12A==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/personalized-medicine-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Digital Health Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ2_m8Gv6eZgYxrKEe9DMZibYWAEGpL6__YTACXCVNgDCjnCMFsRqD07TrnxA3LU1T6JDANVHQJhyTIGLGMzk1LJ__YuENLZZUIO5l2sEFdswf_MGmos7R3a0WPEBvhE1d6kJhjehyPyziftlOw0fBhv\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/digital-health-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Telehealth Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ262yz9GBSZplTX-7IjVf-E1DuFmXWsaWME_6lEzpF85lFLdTpHLsryR4oArwTgk7oEP_14e3dzUtIPG1OPzQr8NakBxOubV3QbcuVigtbZOGatLjmCaBKEvANUGV9gUsM=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/telehealth-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Pharmacy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFouGnGa98M--5CcVRjIoZ3WKGxez0qDaT3KG_CFwPoIN7vyxdq76SnqWE0_Gs6uIpX4b7PZgV2Utv0chYuGmsGjb_UZgoDRCyk-oA2F7epuHKoV6nCX2CVFrfq6bZXxGhW9CDhD3bCjoeqMU2BQls0=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmacy-market<\/a><\/li>\n<\/ol>\n<p><b>About Precedence Research<\/b><\/p>\n<p>Precedence Research is a global market intelligence and consulting company. It provides market sizing and forecasts, competitive and company analysis, customer and buyer intelligence and customized research across healthcare, pharmaceuticals, ICT, energy, chemicals and materials, aerospace and other industries, helping executives and investors make evidence-based decisions.<\/p>\n<p><b>Our Partners<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Towards Healthcare: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GFSDMTrSKZZr9KP8YRNb3Spkx-oVRKmyG5_tZzjsGSfWHNgt9kP5HuV9oM76g-g1hg5LiE5hOtGb31u1tMSbosuVb-89HdZ2VlFebVDKRrlf\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardshealthcare.com\/<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Packaging: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GN9ataoJCpYQscr2b4MD65reM7A2lfHi9n9724fkhqcn5mY0En11UkldNgRqPk_OUp4_acYsXZi_4jlzPw6s1gD5zubVE3sg1v3gwf02C2SR\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardspackaging.com\/<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Chemical &amp; Materials: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GIE14rXFEoFEy-jigip7MW_c37FBhGUuDwj-4tqbeX1T7NpuSu29Yhhk7FeOT1glZ1ameNUyfPFBDeKX2MwP_vDACzgi01PV_QqeclSSXycDIcMhXx9vjWOMjvoRGdTNTA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardschemandmaterials.com\/<\/a>\n<\/li>\n<\/ul>\n<p><b>Connect With Us<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">USA: +1 804 441 9344<\/li>\n<li style=\"margin-bottom:4pt;\">APAC: +61 485 981 310 or +91 87933 22019<\/li>\n<li style=\"margin-bottom:4pt;\">Singapore: +65 3105 1271<\/li>\n<li style=\"margin-bottom:4pt;\">Europe: +44 7383 092 044<\/li>\n<li style=\"margin-bottom:4pt;\">Email: sales@precedenceresearch.com\n<\/li>\n<\/ul>\n<p><b>Social Media<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GPNPAzakTrMOXRZeVcMCnhKHiHolJfo_uQi4yDE3jRp2gIbj3_VKwrYox9wSbRtP1fJ_jbElM1raezSfZq4BJ0-Rk_UEuOyiq4QzzDRnMylOo4zLjS9i43hH_wkKHM1Qy7JVxAfcT5wX0HMs2txkk7U=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.linkedin.com\/company\/precedence-research<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Facebook: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GBMFXthCKq7n8kVeik7v567ROTg4_ysgQqskHVGzxA_c2_0ZajERlcLJyIGcaU4sXIale7LOehHqS_qK9BqhnIEMI_NnrnFG5jKcDl0gr5QR3gnqzBfwLHjN5J1AsT2QoA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.facebook.com\/precedenceresearch<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">X: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GAp7-EooqvRJAYdYd6XLMHzL_-dYK0WRo14wWsL9zJt4k9NGBH-MIRuO8fAMom5PUpSRAJAQQHdEKTbsg6CB4d8=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/x.com\/precedence_r<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Medium: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GrDhDOq8SjfUC_mnxMD_GEWtVaxo2mBXbP9C-yOH24RxSDPmLpO5zvVJhR_0NL13PM_E4lqAY0aMWT81TVIW0v6eLf-_zRSso1oyNHu913jFqH0TqreN9rY60S0bEo4ChA8RqadVW5vqTh_j1TOTVA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/precedence-research.medium.com\/<\/a><\/li>\n<\/ul>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/MzBiZWEyNjctMTQ2Ny00MTQwLThiOTAtZjIxMGFmZTU3N2JkLTEyMTM4NDktMjAyNi0xMS0xOC1lbg==\/tiny\/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>North America Holds 42% of a USD 1.88 Trillion Market, Prescription Drugs 87% and Cancer 19%, While Biologics and Obesity Grow Fastest: Precedence Research Segment, Company and Buyer Intelligence Ottawa, Nov. 18, 2026 (GLOBE NEWSWIRE) &#8212; The global pharmaceutical market is valued at USD 1.88 trillion in 2026, up from USD 1.77 trillion in 2025, [&#8230;]\n","protected":false},"author":1,"featured_media":91505,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-91504","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing\" \/>\n<meta property=\"og:description\" content=\"North America Holds 42% of a USD 1.88 Trillion Market, Prescription Drugs 87% and Cancer 19%, While Biologics and Obesity Grow Fastest: Precedence Res\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-18T17:20:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-19T02:16:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing.png\" \/>\n\t<meta property=\"og:image:width\" content=\"237\" \/>\n\t<meta property=\"og:image:height\" content=\"77\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing\",\"datePublished\":\"2026-11-18T17:20:00+00:00\",\"dateModified\":\"2026-11-19T02:16:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/\"},\"wordCount\":2374,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/\",\"name\":\"Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-11-18T17:20:00+00:00\",\"dateModified\":\"2026-11-19T02:16:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/","og_locale":"en_US","og_type":"article","og_title":"Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing","og_description":"North America Holds 42% of a USD 1.88 Trillion Market, Prescription Drugs 87% and Cancer 19%, While Biologics and Obesity Grow Fastest: Precedence Res","og_url":"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-11-18T17:20:00+00:00","article_modified_time":"2026-11-19T02:16:49+00:00","og_image":[{"width":237,"height":77,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing","datePublished":"2026-11-18T17:20:00+00:00","dateModified":"2026-11-19T02:16:49+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/"},"wordCount":2374,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/","url":"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/","name":"Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-11-18T17:20:00+00:00","dateModified":"2026-11-19T02:16:49+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/pharmaceutical-market-to-reach-usd-3-20-trillion-by-2035-as-obesity-and-oncology-drugs-lead-growth-and-u-s-pricing-deals-and-tariffs-reshape-manufacturing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Pharmaceutical Market to Reach USD 3.20 Trillion by 2035 as Obesity and Oncology Drugs Lead Growth and U.S. Pricing Deals and Tariffs Reshape Manufacturing"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91504","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=91504"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91504\/revisions"}],"predecessor-version":[{"id":91506,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91504\/revisions\/91506"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/91505"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=91504"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=91504"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=91504"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}